2.43
2.43 (0%)
As of Feb 14, 2025
Zentalis Pharmaceuticals Inc [ZNTL]
Source:
Company Overview
Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | (212) 433-3791 |
| Industry | manufacturing |
| CEO | Kimberly Blackwell, M.D. |
| Website | www.zentalis.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $67.4 |
| Operating Profit | $-191.2 |
| Net Income | $-165.9 |
| Net Cash | $5.8 |
Profit Ratios
| Gross Margin | $67.4 |
| Operating Margin | -283.6 |
| Profit as % of Revenues | -40.7% |
| Profit as % of Assets | -33.8% |
| Profit as % of Stockholder Equity | -49.2% |
Management Effectiveness
| Return on Equity | -49.2% |
| Return on Assets | -38.5% |
| Turnover Ratio | 13.7% |
| EBITA | $-191.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $430.3 |
| Total Liabilities | $93.2 |
| Operating Cash Flow | $-170.9 |
| Investing Cash Flow | $176.6 |
| Financing Cash Flow | $0.1 |
